If Helen has done more, then why is that not reflected in the market? Both companies have advanced the tech. ZIOP has some good IL12 data and partners.
XOn doesn't have a Phase II for cancer yet with the PRGN's. That is why I haven't focused on that area yet as to a reason why I own XON. I expect there to be good news eventually in the cancer area, but I don't have any urge to use up message board space in the interim on it. If XON didn't have CART at all, I would still own it.
In terms relative to stock price since the split it is clear who the market likes at least nominally better at this point.
I'm expecting good Q4's for both stocks. I won't though characterize the Fundamentals board as an "only" board. I think the heart therapy has great potential. Hopefully they gives us a meaty update there.